公开(公告)号：US20240002368A1

公开(公告)日：2024-01-04

申请号：US18037965

申请日：2021-11-23

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Hailong Li ,  Wenge Zhong ,  Wei Huang

IPC: C07D403/12 ,  C07D471/04 ,  C07D405/14 ,  C07D403/14 ,  C07D413/14

CPC classification number: C07D403/12 ,  C07D471/04 ,  C07D405/14 ,  C07D403/14 ,  C07D413/14

Abstract: The present disclosure provides compounds of Formula (I) a pharmaceutically acceptable salt, a stereoisomer, or a tautomer thereof, for use in, e.g. treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

公开(公告)号：US20230278991A1

公开(公告)日：2023-09-07

申请号：US18113859

申请日：2023-02-24

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Wenge Zhong ,  Wei Guo

IPC: C07D405/14 ,  C07D417/14 ,  C07D471/04

CPC classification number: C07D405/14 ,  C07D417/14 ,  C07D471/04

Abstract: The present disclosure provides compounds of Formula (I)




and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease.

公开(公告)号：US20210179594A1

公开(公告)日：2021-06-17

申请号：US16950393

申请日：2020-11-17

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Wenge Zhong ,  Wei Guo

IPC: C07D405/14 ,  C07D417/14 ,  C07D471/04

Abstract: The present disclosure provides compounds of Formula (I) and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease.

公开(公告)号：US20230174512A1

公开(公告)日：2023-06-08

申请号：US17922804

申请日：2021-05-04

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Zhilong Hu ,  Hu He ,  Fei Zhang ,  Wenge Zhong ,  Xiaotian Zhu

IPC: C07D401/14 ,  A61K45/06 ,  A61P35/00

CPC classification number: C07D401/14 ,  A61K45/06 ,  A61P35/00

Abstract: The invention provides a compound represented by the following structural formula: (I) or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.

公开(公告)号：US10954221B2

公开(公告)日：2021-03-23

申请号：US16902807

申请日：2020-06-16

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Wenge Zhong ,  Wei Guo

IPC: C07D405/14 ,  C07D417/14 ,  C07D471/04

Abstract: The present disclosure provides compounds of Formula (I) and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease.

公开(公告)号：US20200325121A1

公开(公告)日：2020-10-15

申请号：US16902807

申请日：2020-06-16

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Wenge Zhong ,  Wei Guo

IPC: C07D405/14 ,  C07D471/04 ,  C07D417/14

Abstract: The present disclosure provides compounds of Formula (I) and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease.

公开(公告)号：US20240066031A1

公开(公告)日：2024-02-29

申请号：US18373060

申请日：2023-09-26

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Zhilong Hu ,  Hu He ,  Fei Zhang ,  Wenge Zhong ,  Xiaotian Zhu

IPC: A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  A61K45/06 ,  A61P35/00 ,  C07D401/14 ,  C07D405/14 ,  C07D487/04

CPC classification number: A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  A61K45/06 ,  A61P35/00 ,  C07D401/14 ,  C07D405/14 ,  C07D487/04

Abstract: The invention provides a compound represented by the following structural formula: (I) or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.

公开(公告)号：US20220389037A1

公开(公告)日：2022-12-08

申请号：US17624514

申请日：2020-07-03

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Wenge Zhong ,  Xiaotian Zhu ,  Song Feng ,  Lei Wu ,  Wei Huang ,  Hao Liu ,  Rongqiang Liu ,  Kate Xin Wen ,  Hua Zhou

IPC: C07F9/6561 ,  C07D401/14 ,  C07D405/14 ,  C07D471/04 ,  C07D519/00 ,  C07D491/107 ,  C07D487/04 ,  C07D473/32 ,  C07F9/6558 ,  C07D498/04 ,  A61K45/06

Abstract: Provided herein is a compound represented by structural formula (I-0) or formula (II): or a pharmaceutically acceptable salt or a stereoisomer thereof useful for treating diseases (such as cancer) that are treatable by inhibiting HPK1 activity.

公开(公告)号：US20220024901A1

公开(公告)日：2022-01-27

申请号：US17296078

申请日：2019-11-19

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Wenge Zhong

IPC: C07D405/14 ,  C07D471/04 ,  C07D498/04 ,  C07D471/08

Abstract: Provided are compounds of Formula (I) and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease.

公开(公告)号：US20240051956A1

公开(公告)日：2024-02-15

申请号：US18268914

申请日：2021-12-21

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Kailiang Wang ,  Zhilong Hu ,  Fei Zhang ,  Wei Huang ,  Teng Feng ,  Fei Xiao ,  Wenge Zhong

IPC: C07D471/04 ,  C07D519/00 ,  A61P35/00

CPC classification number: C07D471/04 ,  C07D519/00 ,  A61P35/00

Abstract: The present disclosure provides a compound of Formula (I) a pharmaceutically acceptable salt or a stereoisomer and their use in, e.g. treating a condition, disease or disorder in which the inhibition of the interaction of SOS 1 and a RAS-family protein or RAC1 is of therapeutic benefit, specifically in treating oncological diseases. This disclosure also features compositions containing the same as well as methods of using and making the same.